High purity microfluidic sorting and analysis of circulating tumor cells: towards routine mutation detection.

Authors:
Julien Autebert
Julien Autebert
Université Pierre et Marie Curie
France
Benoit Coudert
Benoit Coudert
Institute of Macromolecular Chemistry
Czech Republic
Laure Saias
Laure Saias
Université Pierre et Marie Curie
France
Ronald Lebofsky
Ronald Lebofsky
Harvard Medical School
United States
Francois-Clement Bidard
Francois-Clement Bidard
Memorial Sloan-Kettering Cancer Center
France

Lab Chip 2015 May;15(9):2090-101

Institut Curie, Centre National de la Recherche Scientifique, Université Pierre et Marie Curie, PSL Research University, Unité Mixte de Recherche 168, 75005 Paris, France.

A new generation of the Ephesia cell capture technology optimized for CTC capture and genetic analysis is presented, characterized in depth and compared with the CellSearch system as a reference. This technology uses magnetic particles bearing tumour-cell specific EpCAM antibodies, self-assembled in a regular array in a microfluidic flow cell. 48,000 high aspect-ratio columns are generated using a magnetic field in a high throughput (>3 ml h(-1)) device and act as sieves to specifically capture the cells of interest through antibody-antigen interactions. Using this device optimized for CTC capture and analysis, we demonstrated the capture of epithelial cells with capture efficiency above 90% for concentrations as low as a few cells per ml. We showed the high specificity of capture with only 0.26% of non-epithelial cells captured for concentrations above 10 million cells per ml. We investigated the capture behavior of cells in the device, and correlated the cell attachment rate with the EpCAM expression on the cell membranes for six different cell lines. We developed and characterized a two-step blood processing method to allow for rapid processing of 10 ml blood tubes in less than 4 hours, and showed a capture rate of 70% for as low as 25 cells spiked in 10 ml blood tubes, with less than 100 contaminating hematopoietic cells. Using this device and procedure, we validated our system on patient samples using an automated cell immunostaining procedure and a semi-automated cell counting method. Our device captured CTCs in 75% of metastatic prostate cancer patients and 80% of metastatic breast cancer patients, and showed similar or better results than the CellSearch device in 10 out of 13 samples. Finally, we demonstrated the possibility of detecting cancer-related PIK3CA gene mutation in 20 cells captured in the chip with a good correlation between the cell count and the quantitation value Cq of the post-capture qPCR.

Download full-text PDF

Source
http://dx.doi.org/10.1039/c5lc00104hDOI Listing

Still can't find the full text of the article?

Sign up to send a request to the authors directly.
May 2015
7 Reads

Publication Analysis

Top Keywords

cells
10
capture
9
cells captured
8
optimized ctc
8
low cells
8
blood tubes
8
cell
8
cells device
8
ctc capture
8
cancer patients
8
device
6
hours capture
4
expression cell
4
tubes hours
4
cell membranes
4
capture rate
4
epcam expression
4
70% low
4
rate epcam
4
rate 70%
4

Similar Publications